Pyxis Oncology, Inc. (PYXS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 6M 12M 18M Q4 '24: 16.1M Q1 '25: 0 Q2 '25: 2.8M Q3 '25: 2.8M Q4 '25: 13.9M Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Gross Profit TTM

0 6M 12M 18M Q4 '24: 15.7M Q4 '24

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q2 '21: -49.4M Q3 '21: -57.9M Q4 '21: -69.7M Q1 '22: -65.4M Q2 '22: -85.2M Q3 '22: -101.9M Q4 '22: -123.5M Q1 '23: -113M Q2 '23: -105.4M Q3 '23: -102.4M Q4 '23: -82.2M Q1 '24: -66.8M Q2 '24: -68.8M Q3 '24: -67.2M Q4 '24: -89.5M Q1 '25: -106.8M Q2 '25: -106.5M Q3 '25: -106.2M Q4 '25: -84.4M Q1 '26: -85.9M Q2 '26: -92.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q4 '20: -12.8M Q1 '21: -47.7M Q2 '21: -52.7M Q3 '21: -63.7M Q4 '21: -76M Q1 '22: -70.5M Q2 '22: -87.9M Q3 '22: -101.4M Q4 '22: -120.7M Q1 '23: -108.6M Q2 '23: -98.9M Q3 '23: -94.3M Q4 '23: -73.8M Q1 '24: -57.8M Q2 '24: -59.2M Q3 '24: -57.4M Q4 '24: -77.3M Q1 '25: -95.2M Q2 '25: -96.3M Q3 '25: -97.1M Q4 '25: -79.6M Q1 '26: -81.7M Q2 '26: -88.7M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 200K 400K 600K Q4 '24: 475K Q4 '24

Operating Cash Flow TTM

-105M -70M -35M 0 35M 70M 105M Q3 '21: -26.3M Q4 '21: -35.3M Q1 '22: -44.3M Q2 '22: -70.8M Q3 '22: -84.1M Q4 '22: -89.3M Q1 '23: -88.5M Q2 '23: -75.8M Q3 '23: -72.8M Q4 '23: -70.7M Q1 '24: -64.6M Q2 '24: -56.6M Q3 '24: -53.6M Q4 '24: -57.7M Q1 '25: -59.5M Q2 '25: -73.8M Q3 '25: -72.4M Q4 '25: -63.5M Q1 '26: -67M Q2 '26: -67.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-105M -70M -35M 0 35M 70M 105M Q3 '21: -26.9M Q4 '21: -35.9M Q1 '22: -44.8M Q2 '22: -71.1M Q3 '22: -88.7M Q4 '22: -95.7M Q1 '23: -99.2M Q2 '23: -88.6M Q3 '23: -81.4M Q4 '23: -77.4M Q1 '24: -67.1M Q2 '24: -56.9M Q3 '24: -53.9M Q4 '24: -57.9M Q4 '21 Q2 '22 Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '21: 1.5M Q3 '21: 1.6M Q1 '22: 32.3M Q2 '22: 32.5M Q3 '22: 32.6M Q1 '23: 35.4M Q2 '23: 38.4M Q3 '23: 41.3M Q1 '24: 51.3M Q2 '24: 60.5M Q3 '24: 60.7M Q1 '25: 61M Q2 '25: 61.9M Q3 '25: 62.6M Q1 '26: 63.5M Q2 '26: 64M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q2 '21: -39.75 Q3 '21: -45.78 Q4 '21: -8.95 Q1 '22: 17.34 Q2 '22: 22.09 Q3 '22: 30.20 Q4 '22: -3.65 Q1 '23: -3.22 Q2 '23: -2.84 Q3 '23: -2.55 Q4 '23: -1.84 Q1 '24: -1.36 Q2 '24: -1.24 Q3 '24: -1.03 Q4 '24: -1.29 Q1 '25: -1.58 Q2 '25: -1.59 Q3 '25: -1.59 Q4 '25: -1.29 Q1 '26: -1.31 Q2 '26: -1.41 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.